10 minutes read

China’s cardiovascular surgery is in a globally leading position — Fuwai Hospital (National Center for Cardiovascular Diseases) performed 18,874 cardiovascular surgeries in 2023, the largest single-center cardiovascular surgery volume in the world (approximately 2.4× Cleveland Clinic’s total system volume), with a 30-day mortality of only 0.4% (below 1% for 15 consecutive years). The Chinese-pioneered Sun’s Procedure has reduced aortic dissection surgery mortality from 20-30% to 2-3%; the domestic TAVI (Venus VenusA) holds >80% market share in China; and domestic ECMO (Hano) has received EU CE MDR certification. Pricing is typically 1/3 to 1/8 of US. This article walks through China’s complex cardiac surgery capabilities by subspecialty, leading centers, domestic innovation, and the practical international patient pathway.

China’s Global Position in Cardiovascular Surgery

Fuwai Hospital (National Center for Cardiovascular Diseases) core data [1]:

  • 18,874 cardiovascular surgeries performed in 2023
  • 30-day mortality 0.4% (below 1% for 15 consecutive years)
  • Approximately 2.4× the surgical volume of Cleveland Clinic’s entire health system
  • Globally recognized as the world’s largest single-center cardiovascular surgery institution

Fudan 2023 Cardiovascular Specialty Reputation Rankings [2]:

  1. Fuwai Hospital (15 consecutive years #1)
  2. Fudan University Zhongshan Hospital (Academician Ge Junbo)
  3. Beijing Anzhen Hospital (Academician Sun Lizhong, birthplace of Sun’s Procedure)
  4. General Hospital of Northern Theater Command
  5. Zhejiang University Second Affiliated Hospital

China’s Leading Cardiac Surgery Centers

Fuwai Hospital (National Center for Cardiovascular Diseases) [1]

  • World’s largest single-center cardiovascular surgery institution
  • Comprehensive capability covering complex congenital heart, CABG, valve, heart transplant
  • International Medical Department serves international patients (see Article 4)

Fudan University Zhongshan Hospital (Academician Ge Junbo’s team)

  • East China TAVI / TEER leader
  • Top interventional cardiology center
  • Admitted to Shanghai’s 13-hospital International Medical Tourism Pilot

Beijing Anzhen Hospital [3]

  • Major Vascular Disease Diagnostic and Research Center
  • Academician Sun Lizhong, birthplace of Sun’s Procedure
  • National leader in aortic dissection surgery

Wuhan Union Hospital

  • 310 heart transplants over the past 5 years (success rate 97.6%)
  • National #1 in pediatric heart transplant volume

Guangdong Provincial People’s Hospital Cardiac Surgery

  • Historical annual major surgery volume 4,805 (2014)
  • Pediatric congenital heart + complex valve surgery

Other major centers:

  • Peking Union Medical College Hospital Cardiac Surgery
  • Shanghai Renji Hospital Cardiac Surgery
  • Sun Yat-sen 1st Affiliated Hospital Cardiac Surgery
  • Xijing Hospital Cardiovascular Surgery
  • West China Hospital, Sichuan University Cardiac Surgery
  • Zhejiang University 2nd Affiliated Hospital Cardiac Surgery
  • Shanghai Children’s Medical Center Cardiac Surgery (pediatric congenital heart specialty)

Eight Major Complex Cardiac Surgery Subspecialties

1. Coronary Artery Bypass Graft (CABG)

  • Chinese annual volume mature at Fuwai, Anzhen, West China, and other centers
  • Compared with PCI (coronary stenting), complex three-vessel disease or left main disease typically prefers CABG
  • OPCAB (off-pump coronary bypass) is routine at top domestic centers
  • Full arterial CABG (using all arterial grafts) on par with international standards

2. TAVI (Transcatheter Aortic Valve Implantation) — China Leads Globally in Domestic Substitution

TAVI is one of the most significant breakthroughs in cardiovascular interventional therapy of the past decade:

China TAVI data [4]:

  • 2023 cumulative 13,572 cases
  • 2024 projected to exceed 20,000 cases
  • NMPA-approved 4 domestic TAVI valves:
    • Venus VenusA-Valve (first NMPA approval in 2017, China’s first)
    • Jenscare J-Valve
    • MicroPort VitaFlow
    • Peijia TaurusOne
  • Domestic TAVR market share consistently >80%
  • International imported brands: Medtronic CoreValve, Edwards SAPIEN also accessible in China

Practical implication for international patients: Chinese TAVI pricing is substantially lower than US (~$38-46K vs US ~$71K commercial median), and TAVI surgical experience density is among the highest globally.

3. TEER (Transcatheter Edge-to-Edge Repair, Mitral Valve)

TEER data [5]:

  • Cumulative implants 8,659 (through 2025)
  • 2025 single-year 4,334 cases
  • MitraClip (Abbott imported) 2023 single-year 1,282 cases
  • 3 domestic TEER products:
    • Hanyu ValveClamp (transapical) — first domestic NMPA approval September 2023
    • Dejin DragonFly (transfemoral) — 2023
    • Endo Neonova — 2025

Indications: mitral regurgitation (functional / degenerative) — especially in patients at high surgical risk

4. Complex Aortic Surgery — Sun’s Procedure

Sun’s Procedure = China’s greatest contribution to global aortic surgery [3]:

  • Pioneered by Academician Sun Lizhong at Beijing Anzhen Hospital
  • Combined with Frozen Elephant Trunk (FET) sandwich-type stented vascular graft
  • Cumulative >7,900 cases
  • 78.6% of recent Chinese ATAAD (Acute Type A Aortic Dissection) cases use Sun’s procedure FET
  • Surgical mortality reduced from 20-30% to 2-3% — global-level impact

Applications:

  • Type A aortic dissection
  • Complex aortic arch pathology
  • Thoracoabdominal aortic aneurysm involving the aortic arch

Top centers: Beijing Anzhen, Fuwai, Changhai Hospital, Fudan Zhongshan

5. Complex Congenital Heart Disease Surgery

Indications:

  • Transposition of the great arteries (TGA)
  • Single ventricle (HLHS, tricuspid atresia, etc.)
  • Complex tetralogy of Fallot
  • Total anomalous pulmonary venous return
  • Complex atrioventricular septal defects

Top centers:

  • Fuwai Hospital (adult + pediatric complex congenital heart)
  • Shanghai Children’s Medical Center (pediatric congenital heart specialty, see Article 28)
  • Guangdong Provincial People’s Hospital (pediatric congenital heart)
  • Wuhan Union Hospital (pediatric congenital heart + heart transplant)

Fontan procedure and other multi-stage single-ventricle correction surgeries are mature at China’s top centers.

6. Heart Transplantation

China heart transplant data [6]:

  • 2024: 1,062 transplants performed nationwide across 64 hospitals (+6.7% YoY)
  • 1-year survival rate 85%
  • 5-year survival rate 71% — on par with international standards
  • Wuhan Union 310 cases over 5 years (success rate 97.6%); national #1 in pediatric heart transplant volume

For international patients: Chinese heart transplant primarily serves Chinese domestic patients. International patient reception is mainly limited to consultations supporting family member arrangements — independent travel to China specifically for heart transplant must navigate China’s regulatory framework (see Article 23 on organ transplant regulations).

7. Valve Surgery (Open Surgery)

  • Aortic valve replacement (SAVR) — mechanical valve / biological valve
  • Mitral valve repair — valve repair preferred over replacement
  • Tricuspid valve surgery
  • Multi-valve combined surgery
  • Minimally invasive valve surgery (mini-thoracotomy)

8. Heart Failure Surgery

  • Left ventricular assist device (LVAD): Chinese domestic LVAD has entered clinical trials and early application
  • Cardiac resynchronization therapy (CRT-D)
  • ICD implantation

Chinese Domestic Cardiovascular Innovation

Domestic TAVI:

  • 4 domestic TAVI valves including Venus VenusA-Valve
  • Domestic market share >80% — one of the most successful domestic substitution cases globally

Domestic TEER:

  • 3 domestic TEER products: Hanyu, Dejin, Endo

Domestic ECMO [7]:

  • Hano Medical first NMPA approval January 2023
  • 2024 domestic production rate 29.1%
  • Hano alone 12.1% market share, #1 in new installations
  • EU CE MDR certification obtained (first of its kind) — Chinese ECMO going international

Global significance of Chinese high-end medical devices:

  • Chinese cardiovascular device industry has moved from “all imported” to “domestic substitution + overseas expansion”
  • Domestic pricing advantages allow international patients to access international-grade technology at lower cost

Pricing Comparison (at 1 USD = 6.5 RMB)

Procedure US All-Inclusive Cost (USD) China Estimate
CABG Medicare median $44,149; commercial median $57,240; self-pay median $75,047 [8] $12,000–$23,000 (Chinese Tier-3A approximately 80,000–150,000 RMB)
TAVI Medicare median $37,865; commercial median $71,312; list price median $166,714 [9] $38,000–$46,000 (with device approximately 250,000–300,000 RMB)
TEER US typically $50,000–$100,000+ China estimate $25,000–$50,000
SAVR (valve replacement) Typically $40,000–$80,000 China average total cost approximately $19,300 (2015-2016 data)
Heart transplant Estimated $1.3M–$1.66M (including perioperative + lifelong medication); Medicare median $216,927 [10] $80,000–$150,000 (surgery + perioperative)
Aortic dissection repair (including Sun’s Procedure) US $100K–$200K+ $30,000–$60,000

Core value: Chinese complex cardiac surgery pricing is approximately 1/3 to 1/8 of US.

Practical Pathway for International Cardiac Surgery Patients in China

Best-suited international patients:

  1. Complex aortic dissection — Sun’s Procedure originated in China, world-class
  2. Complex congenital heart disease (pediatric and adult) — Fuwai, Wuhan Union, Guangdong Provincial People’s
  3. TAVI / TEER interventional therapy — Chinese experience density among the world’s highest, pricing advantage
  4. Complex valve or multi-valve surgery — Fuwai, Fudan Zhongshan, Anzhen
  5. Long cardiac surgery waiting times in home country (Europe often months)
  6. Unaffordable cardiac surgery costs in home country

Typical timeline:

Phase Duration
Pre-travel evaluation + MDT 4–6 weeks (remote)
Arrival + on-site evaluation + surgical preparation 1 week
Surgery + ICU 5–10 days
Ward recovery + early rehabilitation 1–2 weeks
Discharge + early follow-up 1 week

Total time in China: 3–5 weeks (depending on surgical complexity)

Common Questions

Is Fuwai Hospital really the world’s largest cardiac surgery center? Yes. 18,874 cardiovascular surgeries in 2023, approximately 2.4× Cleveland Clinic’s total system volume, with surgical mortality (0.4%) on par with international top centers.

How does China’s TAVI compare with the US? Domestic TAVI clinical data has been published in international journals, on par with imported brands (Medtronic CoreValve, Edwards SAPIEN). China’s TAVI experience density is among the world’s highest — rapid year-over-year volume growth. Pricing is substantially lower than US.

Can Sun’s Procedure be done at Fuwai, or only Anzhen? Sun’s Procedure originated at Anzhen, but the technique has been widely disseminated nationally — Fuwai, Changhai Hospital, Fudan Zhongshan, and other top centers can all perform it. For complex aortic dissection patients, Beijing Anzhen (the originating center) or Fuwai is recommended as priority.

Can international patients receive heart transplants in China? Chinese heart transplant primarily serves Chinese patients. For international patients, see Article 23 on organ transplant regulations — living donor heart transplant doesn’t exist in this category, and DDLT resources are primarily allocated to Chinese citizens. Independent international patient access to heart transplant in China requires case-by-case consultation.

What’s the value of bringing pediatric complex congenital heart patients to China? Very high — Fuwai, Wuhan Union, Shanghai Children’s Medical Center, Guangdong Provincial People’s are the top domestic centers, with mature experience in Fontan and other multi-stage single-ventricle correction surgeries, at pricing substantially below US (see Article 28).

Can post-operative follow-up be done remotely by my home country cardiologist? Yes. The key is to stabilize 1–2 months post-surgery in China before transitioning to your home country cardiologist. MedCareInChina facilitates this.

How does international insurance cover cardiac surgery? Most premium international medical insurance plans (MSH International, Cigna Global, Bupa Global, etc.) cover cardiac surgery. Confirm lifetime cap and pre-authorization workflow before traveling.

Bottom Line

Core value of complex cardiac surgery in China:

  • Fuwai Hospital is the world’s largest single-center cardiovascular surgery institution (annual 18,874 cases, 0.4% mortality)
  • Sun’s Procedure global-level contribution (aortic dissection mortality 20-30% → 2-3%)
  • Domestic TAVI >80% market share — pricing advantage + clinical maturity
  • Domestic ECMO with CE MDR — Chinese cardiovascular devices going international
  • Pricing approximately 1/3 to 1/8 of US
  • Mature top centers: Fuwai, Fudan Zhongshan, Anzhen, Wuhan Union, Guangdong Provincial People’s

Best-suited international cardiac surgery patients for travel to China:

  • Complex aortic dissection (Sun’s Procedure)
  • Complex congenital heart disease (adult + pediatric)
  • TAVI / TEER interventional therapy
  • Complex valve surgery
  • Patients with long home country wait times or unaffordable costs

Total time in China: 3–5 weeks (depending on surgical complexity)

If you or a family member has a complex cardiac surgery indication, MedCareInChina matches the most appropriate Chinese cardiac surgery center and team based on the specific diagnosis — while coordinating visa, accommodation, insurance, and integration with your home country cardiology team.

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. Fuwai Hospital 2023 data — 18,874 cardiovascular surgeries, 30-day mortality 0.4% (below 1% for 15 consecutive years). Source: Fuwai Cardiac Surgery Annual Report 2023 https://www.fuwaihospital.org/Sites/Uploaded/File/2025/3/%E5%A4%96%E7%A7%91%E5%B9%B4%E6%8A%A52023.pdf ; Cleveland Clinic comparison: https://consultqd.clevelandclinic.org/vital-statistics-in-adult-cardiac-surgery-valve-surgery-and-aorta-surgery
  2. Fudan 2023 Cardiovascular Specialty Reputation Rankings — Fuwai 15 consecutive years #1. Source: https://rank.cn-healthcare.com/fudan/specialty-general/year/2022/sid/7
  3. Beijing Anzhen Sun’s Procedure — Originated by Academician Sun Lizhong. Cumulative 7,900+ cases; 78.6% of recent Chinese ATAAD cases use Sun’s procedure FET; surgical mortality reduced from 20-30% to 2-3%. Sources: People’s Daily Sun Lizhong interview http://paper.people.com.cn/jksb/html/2023-01/13/content_25962334.htm ; Annals of Cardiothoracic Surgery https://pmc.ncbi.nlm.nih.gov/articles/PMC3791186/ ; PubMed 41099002 https://pubmed.ncbi.nlm.nih.gov/41099002/
  4. China TAVI cumulative data — 2023 cumulative 13,572 cases; 4 domestic TAVI products (Venus VenusA, Jenscare J-Valve, MicroPort VitaFlow, Peijia TaurusOne), Venus market share >80%. Source: Structural Heart Disease 2023 Annual Report https://docbook.com.cn/information/1596
  5. China TEER data — Cumulative 8,659 cases through 2025. 3 domestic TEER (Hanyu ValveClamp, Dejin DragonFly, Endo Neonova). Sources: 2025 Transcatheter Mitral Regurgitation Treatment Annual Report https://docbook.com.cn/information/3531 ; Yicai https://m.yicai.com/news/101854717.html
  6. China heart transplant 2024 data — 1,062 cases nationwide across 64 hospitals (+6.7%), 1-year/5-year survival 85%/71%; Wuhan Union 310 cases over 5 years (success rate 97.6%). Sources: 2024 China Heart Transplant Literature Review https://www.organtranspl.com/article/doi/10.12464/j.issn.1674-7445.2025131 ; Wuhan Union https://www.whuh.com/info/1021/58181.htm
  7. Domestic ECMO Hano Medical — January 2023 first NMPA approval, CE MDR certification (first of its kind). 2024 domestic production rate 29.1%. Sources: Tencent News https://news.qq.com/rain/a/20250128A020NK00 ; Economic Reference Daily http://www.jjckb.cn/2024-06/26/c_1310779568.htm
  8. US CABG pricing — Medicare median $44,149; commercial median $57,240; self-pay median $75,047. Source: JAHA https://www.ahajournals.org/doi/10.1161/JAHA.123.031982
  9. US TAVI pricing — Medicare median $37,865; commercial median $71,312; list price median $166,714. Source: AHA Journal https://www.ahajournals.org/doi/abs/10.1161/circ.150.suppl_1.4145176
  10. US heart transplant pricing — Estimated $1.3M–$1.66M (including perioperative + lifelong medication); Medicare median $216,927. Sources: Resolve Medical Bills https://www.resolvemedicalbills.com/blog/the-true-cost-of-a-heart-transplant-in-the-us ; Milliman 2025 https://www.milliman.com/en/insight/2025-us-organ-and-tissue-transplants-costs-utilization